Hypertension and primary health-care: Impact of new studies;Hipertensión arterial y atención primaria: Impacto de neuvos estudios

Medicina Clinica

Volumn 121, Issue 1, 2003, Pages 21-22

  de la Figuera, Mariano ^a   Navarro, Jorge ^b  

^a CAP La Mina   (Spain)

^b CS Salvador PauValencia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; IRBESARTAN; LISINOPRIL; LOSARTAN; THIAZIDE DIURETIC AGENT;

CARDIOVASCULAR RISK; DRUG EFFICACY; EDITORIAL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; MORBIDITY; MORTALITY; PREVALENCE; PRIMARY HEALTH CARE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; VASCULAR DISEASE;

EID: 0038486672     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(03)74114-1     Document Type: Editorial

References (9)

1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
2. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, et al. Comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
3. Pitt B, Poole-Wilson PA, Segal R, Martínez Fditein K, Camm AJ, Kostam MA, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart faliure: randomised trial -the Losartan Heart Failure Survival Study-ELITE II. Lancet 2000;355:1582-7.
4. Cohn JN, Tognoni G, for the Val-HeFT Investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronich heart failure. N Engl J Med 2001;345:1667-75.
5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
6. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen SP, for the Irbesartan in Patients with Type 2 Diabetes and Microabuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
7. Benner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al, for the RENAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
8. Dahlöf B, Devereux RB, Kjldsen SE, Julius S, Beevers G, De Faire U, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against antenolol. Lancet 2002;359:995-1003.
9. Lindhom LH, Visen H, Dahlöf B, Devereux RB, Beevers G, De Faire U, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intevention for Endpoint reduction in hypertension study (LIFE): a randomised trial against antenolol. Lancet 2002;359:1004-10.